Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (92,141)	$ (37,907)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	49,974	52,993
Non-cash interest	8,138	1,364
Amortization of debt issuance cost	946	598
Losses from investments in investees	3	79
Equity-based compensation – employees and non-employees	5,199	5,527
Realized loss (gain) on disposal of fixed assets and sales of equity securities	(69)	2,075
Change in fair value of equity securities and derivative instruments	(59,248)	6,146
Loss on conversion convertible senior notes	757	0
Contingent consideration	0	102
Deferred income tax (benefit) provision	(4,477)	1,753
Changes in assets and liabilities:
Accounts receivable, net	15,353	(81,822)
Inventory, net	1,732	2,749
Other current assets and prepaid expenses	(7,817)	1,279
Other assets	(116)	(1,915)
Accounts payable	13,688	20,210
Foreign currency measurement	2,638	(1,318)
Contract liabilities	0	2
Accrued expenses and other liabilities	3,439	5,073
Net cash used in operating activities	(62,001)	(23,012)
Cash flows from investing activities:
Investments in investees	0	(5,000)
Proceeds from the sale of property, plant and equipment	103	842
Capital expenditures	(11,660)	(9,050)
Net cash used in investing activities	(11,557)	(13,208)
Cash flows from financing activities:
Issuance of 3.00% convertible senior notes, net (including related parties)	230,000	0
Issuance of 3.75% 2029 convertible notes, debt issuance cost	(8,562)	0
Share repurchase	(50,000)	0
Proceeds from the exercise of common stock options	(208)	(301)
Borrowings on lines of credit	317,811	341,850
Repayments of lines of credit	(324,256)	(348,206)
Redemption of 2025 Notes and 2033 Senior Notes	(146,287)	(3,000)
Net cash provided by (used in) financing activities	18,498	(9,657)
Effect of exchange rate changes on cash and cash equivalents	(245)	794
Net decrease in cash and cash equivalents	(55,305)	(45,083)
Cash and cash equivalents at beginning of period	95,881	153,191
Cash and cash equivalents at end of period	40,576	108,108
SUPPLEMENTAL INFORMATION:
Interest paid	3,517	4,204
Income taxes paid, net of refunds	1,576	685
Assets acquired by finance leases	0	181
Non-cash financing:
Common stock options, warrants, and restricted stock units surrendered in net exercise	208	301
Fair value of shares received related to milestone achieved from GeneDx Holdings	$ 0	$ 6,689